A Review of the Current Approach and Treatment Landscape for Stage III Non-Small Cell Lung Cancer

被引：4

作者：

Sridhar, Arthi ^{[1
]}

Khan, Hina ^{[2
]}

Yohannan, Binoy ^{[3
]}

Chan, Kok Hoe ^{[2
]}

Kataria, Nilansh ^{[4
]}

Jafri, Syed Hasan ^{[2
]}

机构：

[1] Mayo Clin, Dept Oncol, Rochester, MN 55901 USA

[2] Univ Texas Hlth Sci Ctr Houston, Dept Internal Med, Div Hematol & Oncol, Houston, TX 77030 USA

[3] Mayo Clin, Dept Hematol, Rochester, MN 55901 USA

[4] MedStar Washington Hosp Ctr, Dept Internal Med, Washington, DC 20010 USA

来源：

JOURNAL OF CLINICAL MEDICINE | 2024年 / 13卷 / 09期

关键词：

precision; oncology; personalized; PD-L1; immunotherapy; targeted; osimertinib; durvalumab; radiation; chemotherapy; POSITRON-EMISSION-TOMOGRAPHY; SOUTHWEST-ONCOLOGY-GROUP; PHASE-III; INDUCTION CHEMOTHERAPY; NEOADJUVANT ATEZOLIZUMAB; CONSOLIDATION DOCETAXEL; SURGICAL RESECTION; PLUS CHEMOTHERAPY; RISK-FACTORS; 8TH EDITION;

D O I：

10.3390/jcm13092633

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The therapeutic landscape of the management of stage III non-small cell lung cancer (NSCLC) has drastically evolved with the incorporation of immunotherapy and targeted therapy. Stage III NSCLC accounts for one-third of the cases and the treatment strategy of these locally advanced presentations are diverse, ranging from surgical to non-surgical options; with the incorporation of chemo-immunotherapy, radiation, and targeted therapies wherever applicable. The staging of this disease has also changed, and it is essential to have a strong multidisciplinary approach to do justice to patient care. In this article, we aim to navigate the nuanced approaches in the diagnosis and treatment of stage III NSCLC and expand on the evolution of the management of this disease.

引用

页数：21

共 102 条

[1] Pattern and predictors of occult mediastinal lymph node involvement in non-small cell lung cancer patients with negative mediastinal uptake on positron emission tomography [J].

Al-Sarraf, Nael ;

Aziz, Rashid ;

Gately, Kathy ;

Lucey, Julie ;

Wilson, Lorraine ;

McGovern, Eillish ;

Young, Vincent .

EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2008, 33 (01) :104-109

[2] Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial [J].

Albain, Kathy S. ;

Swann, R. Suzanne ;

Rusch, Valerie W. ;

Turrisi, Andrew T., III ;

Shepherd, Frances A. ;

Smith, Colum ;

Chen, Yuhchyau ;

Livingston, Robert B. ;

Feins, Richard H. ;

Gandara, David R. ;

Fry, Willard A. ;

Darling, Gail ;

Johnson, David H. ;

Green, Mark R. ;

Miller, Robert C. ;

Ley, Joanne ;

Sause, Willliam T. ;

Cox, James D. .

LANCET, 2009, 374 (9687) :379-386

[3] Concurrent cisplatin, etoposide, and chest radiotherapy in Pathologic stage IIIB non-small-cell lung cancer: A Southwest Oncology Group Phase II Study, SWOG 9019 [J].

Albain, KS ;

Crowley, JJ ;

Turrisi, AT ;

Gandara, DR ;

Farrar, WB ;

Clark, JI ;

Beasley, KR ;

Livingston, RB .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (16) :3454-3460

[4]

ALBERTI W, 1995, BRIT MED J, V311, P899

[5] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Kurata, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

Carpeno, J. de Castro ;

Faivre-Finn, C. ;

Reck, M. ;

Vansteenkiste, J. ;

Spigel, D. R. ;

Wadsworth, C. ;

Melillo, G. ;

Taboada, M. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) :2342-2350

[6] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Yokoi, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

de Castro Carpeno, J. ;

Wadsworth, C. ;

Melillo, G. ;

Jiang, H. ;

Huang, Y. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929

[7] Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non-Small-Cell Lung Cancer [J].

Auperin, Anne ;

Le Pechoux, Cecile ;

Rolland, Estelle ;

Curran, Walter J. ;

Furuse, Kiyoyuki ;

Fournel, Pierre ;

Belderbos, Jose ;

Clamon, Gerald ;

Ulutin, Hakki Cuneyt ;

Paulus, Rebecca ;

Yamanaka, Takeharu ;

Bozonnat, Marie-Cecile ;

Uitterhoeve, Apollonia ;

Wang, Xiaofei ;

Stewart, Lesley ;

Arriagada, Rodrigo ;

Burdett, Sarah ;

Pignon, Jean-Pierre .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) :2181-2190

[8] Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: A randomized phase II locally advanced multi-modality protocol [J].

Belani, CP ;

Choy, H ;

Bonomi, P ;

Scott, C ;

Travis, P ;

Haluschak, J ;

Curran, WJ .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5883-5891

[9] Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): Results from the phase II PRINCEPS trial [J].

Besse, B. ;

Adam, J. ;

Cozic, N. ;

Chaput-Gras, N. ;

Planchard, D. ;

Mezquita, L. ;

Remon Masip, J. ;

Lavaud, P. ;

Naltet, C. ;

Gazzah, A. ;

de Montpreville, V. Thomas ;

Ghigna, M. -R. ;

Mussot, S. ;

Fadel, E. ;

Mabille, L. ;

Duchemann, B. ;

Barlesi, F. ;

Soria, J-C. ;

Caramella, C. ;

Mercier, O. .

ANNALS OF ONCOLOGY, 2020, 31 :S794-S795

[10]

Besse B., 2023, Immuno-Oncology Technology, V20, P100589, DOI [10.1016/j.iotech.2023.100592, DOI 10.1016/J.IOTECH.2023.100592]

← 1 2 3 4 5 6 7 8 9 10 →